Citigroup’s Immunocore IMCR Stock Holding History

Citigroup’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$953K	Buy	30,000 +5,000	+20%	+$148K	﹤0.01%	3477
2026 Q1	$754K	Hold	25,000	–	–	﹤0.01%	3295
2025 Q4	$868K	Sell	25,000 -49,600	-66%	-$1.75M	﹤0.01%	3222
2025 Q3	$2.71M	Sell	74,600 -30,000	-29%	-$1.02M	﹤0.01%	2416
2025 Q2	$3.28M	Buy	104,600 +49,600	+90%	+$1.54M	﹤0.01%	2254
2025 Q1	$1.63M	Buy	55,000 +30,000	+120%	+$900K	﹤0.01%	2889
2024 Q4	$738K	Hold	25,000	–	–	﹤0.01%	3581
2024 Q3	$778K	Hold	25,000	–	–	﹤0.01%	3454
2024 Q2	$847K	Buy	+25,000	New	+$1.28M	﹤0.01%	3026
2024 Q1	–	Sell	-25,000	Closed	-$1.71M	–	5741
2023 Q4	$1.71M	Buy	+25,000	New	+$1.3M	﹤0.01%	2376
2023 Q3	–	Sell	-11,000	Closed	-$660K	–	5721
2023 Q2	$660K	Buy	+11,000	New	+$628K	﹤0.01%	3162

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citigroup's IMCR Position: Q2 2026 in Review

Citigroup increased its Immunocore (IMCR) stake by 376% in Q2 2026, buying an estimated $503K and bringing the position to 21,514 shares worth $683K. The position accounts for ﹤0.01% of the portfolio, ranked #3725.

Citigroup first reported a position in IMCR in Q4 2022 and has held it in 15 quarters since. The position peaked at $19.9M in Q2 2025. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

Citigroup held 21,514 shares of Immunocore worth $683K as of Q2 2026.
Citigroup bought 16,997 Immunocore shares in Q2 2026, an estimated $503K.
Immunocore made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3725 holding.
Citigroup first reported a position in Immunocore in Q4 2022 and has held it in 15 quarters since.
Citigroup's Immunocore position peaked at $19.9M in Q2 2025.
135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.